Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Acquisitions & Divestments (2020 - 2025)

Historic Change in Acquisitions & Divestments for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $74.1 million.

  • Lyell Immunopharma's Change in Acquisitions & Divestments fell 4442.95% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year decrease of 2337.49%. This contributed to the annual value of $548.9 million for FY2024, which is 1728.01% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Change in Acquisitions & Divestments is $74.1 million, which was down 4442.95% from $93.5 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Change in Acquisitions & Divestments peaked at $204.2 million during Q1 2021, and registered a low of $70.3 million during Q4 2021.
  • Its 5-year average for Change in Acquisitions & Divestments is $135.3 million, with a median of $133.4 million in 2024.
  • As far as peak fluctuations go, Lyell Immunopharma's Change in Acquisitions & Divestments plummeted by 6580.79% in 2021, and later surged by 7823.88% in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Change in Acquisitions & Divestments stood at $70.3 million in 2021, then skyrocketed by 57.68% to $110.9 million in 2022, then surged by 40.78% to $156.1 million in 2023, then decreased by 20.77% to $123.7 million in 2024, then plummeted by 40.07% to $74.1 million in 2025.
  • Its last three reported values are $74.1 million in Q3 2025, $93.5 million for Q2 2025, and $154.1 million during Q1 2025.